Henry Meds vs Hims & Hers (2026): prices, structure, verdict

On tirzepatide, only Henry Meds↗ has a rankable figure: $349 a month all-in; Hims & Hers↗ routes tirzepatide through brand channels without a single compounded cash price — its cost depends on coverage or the manufacturer programs (Zepbound vials $299–$449; Wegovy $349).

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only Henry Meds has a rankable figure: $179 a month all-in; Hims & Hers routes semaglutide through brand channels without a single compounded cash price — its cost depends on coverage or the manufacturer programs (Zepbound vials $299–$449; Wegovy $349).

§ Side by side

§ Each record, read aloud

The two records, condensed

Henry Meds: the record, condensed

On tirzepatide, the number that matters at Henry Meds is $349 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $349 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.

Henry Meds’s semaglutide program bills $179 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Henry Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $179 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

Hims & Hers: the record, condensed

Hims & Hers routes tirzepatide through brand product — no single compounded cash figure exists to rank. The reference prices live one layer down: Zepbound (LillyDirect), $299–$449 a month cash, or whatever your insurance turns those numbers into.

On semaglutide, Hims & Hers is a brand channel rather than a priced product: it prescribes the FDA-approved medication, and what you pay depends on coverage or the manufacturer cash programs (Wegovy (NovoCare) at $199–$349).

Operationally at Hims & Hers: shipping included; commitment plan recurs; cancellation plan recurs until cancelled; pharmacy named (brand fulfillment; compounded program closed to new patients); states: 50 states; evidence no public price, captured 2026-08-05. The full record with source and archive links: the Hims & Hers page · visit Hims & Hers ↗

§ Structure vs structure

Everything besides the price

Coverage: Henry Meds publishes “most states”; Hims & Hers publishes “50 states” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: Hims & Hers names its network (brand fulfillment; compounded program closed to new patients); Henry Meds does not, which shifts the burden of verification onto your intake questions.

Exit terms: Henry Meds — none month-to-month; check terms before prepaying. Hims & Hers — plan recurs; plan recurs until cancelled.

Evidence: Henry Meds third-party reported (captured 2026-08-05); Hims & Hers no public price (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

§ If you move

Switching between Henry Meds and Hims & Hers

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Henry Meds: check terms before prepaying; Hims & Hers: plan recurs until cancelled) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings